Dupilumab in type 2 airway inflammation-a step forward in targeted therapy for COPD.

Autor:	Tan RVS; Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom., Aung HWW; Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom., Flynn C; Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom., Greening NJ; Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom., Brightling CE; Institute for Lung Health, National Institute for Health Research Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom. Electronic address: ceb17@le.ac.uk.
Jazyk:	angličtina
Zdroj:	The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Feb; Vol. 153 (2), pp. 404-406. Date of Electronic Publication: 2023 Nov 07.
DOI:	10.1016/j.jaci.2023.10.022
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect